AFP and hepatocellular carcinoma: Though AFP performances are not generally satisfactory, Yoshimasu et al. identified AFP and AFP-L3% of possible interest as circulating biomarkers to assess the risk of HCC occurrence or recurrence in DAA-treated patients [86].